7 Results for "

VEGF siRNA

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "VEGF siRNA" in MCE Product Catalog:

Cat. No.: HY-153484A
CAS No.: 849758-52-7
Research Areas:  

Neurological Disease

Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration .
loading...
    loading...
Cat. No.: HY-177614
Synonyms: AD3133 sodium
Target:  

VEGFR

Research Areas:  

Cancer

ALN-3133 sodium is a siRNA that targets VEGF, and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for kinesin spindle protein (KSP) and VEGF with potential antitumor activity.
loading...
    loading...
Cat. No.: HY-177613
CAS No.: 3031494-36-4
Synonyms: AD12115
Target:  

Kinesin

Research Areas:  

Cancer

ALN-12115 is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
loading...
    loading...
Cat. No.: HY-177613A
Synonyms: AD12115 sodium
Target:  

Kinesin

Research Areas:  

Cancer

ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
loading...
    loading...
Cat. No.: HY-153484
CAS No.: 959961-96-7
Research Areas:  

Neurological Disease

Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration .
loading...
    loading...
Cat. No.: HY-153484D
Target:  

Fluorescent Dye

Research Areas:  

Others

FAM labled Bevasiranib sodiumis a FAM labled Bevasiranib sodium. Bevasiranib sodium is an siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA and can be used in research related to macular degeneration.
loading...
    loading...
Cat. No.: HY-153484E
Target:  

Fluorescent Dye

Research Areas:  

Others

Cy3-labeled Bevasiranib sodium is Bevasiranib sodium conjugated with the Cy3 fluorophore. Bevasiranib sodium is an siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex (RISC) to degrade VEGF-A mRNA and can be used in research related to macular degeneration.
loading...
    loading...